This is a preview of subscription content, log in via an institution to check access.
References
Epigenomics. Epigenomics AG validates DNA methylation test as predictor of disease recurrence in breast cancer patients. Media release: 17 May 2005
European Pharmaceuticals. Epigenomics: Latest breast cancer marker data as expected. Lehman Brothers Equity Research (2005)
Nanogen. Study using Nanogen assay confirms NT-proBNP to have utility as predictor of mortality in patients with severe congestive heart failure. Media release: 8 Jun 2005
Stanton E, Hansen M, Wijeysundera HC, et al. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail 2005; 7 (4): 557–65
Loyola University Health System. Loyola researchers discover congestive heart failure biological marker which speeds diagnosis, treatment. Media release: 7 Jun 2005
National Institute of General Medical Sciences. Genetic variation alters response to common anti-clotting drug. Media Release: 2 Jun 2005
EurekAlert. Phase I study examines biomarkers for response to erlotinib in glioma. Media release: 14 Jun 2005
Rights and permissions
About this article
Cite this article
Diagnostic Developments. Pharmaceutical & Diagnostic Innovation 3, 16–18 (2005). https://doi.org/10.1007/BF03259644
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259644